Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04742673 · ClinicalTrials.gov registry record · Phase 2
Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT04742673 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 46 participants.
The verdict
NCT04742673, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This proof-of-concept study examines whether the acute brain dysfunction that occurs in critically ill patients is improved by administration of intravenous guanfacine.
Interventions
- DRUG Placebo
- DRUG Guanfacine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-05-04 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04742673
The ClinicalTrials.gov registry entry for NCT04742673 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04742673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04742673 about?
NCT04742673 is a clinical study titled "Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study". This proof-of-concept study examines whether the acute brain dysfunction that occurs in critically ill patients is improved by administration of intravenous guanfacine.
What is the current status of trial NCT04742673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2021-05-04. Estimated completion is 2025-11-30.
What interventions are being tested in trial NCT04742673?
The interventions under investigation include: Placebo (DRUG), Guanfacine (DRUG).
Who is sponsoring clinical trial NCT04742673?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.